Physician profile
Heather Straight
NPI 1841292786
$3,449.69
in general payments reported to CMS, 2019-2025
22 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $36.02 · 2021: $16.10 · 2022: $277 · 2023: $522 · 2024: $2,287 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,950 · Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,950.00 |
| Food and Beverage | $984.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,950.00 | 2024 | |
| Novo Nordisk INC | $272.28 | 2020-2024 | Ozempic, Rybelsus |
| Amgen INC. | $124.12 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $118.09 | 2022-2024 | |
| Boston Scientific Corporation | $111.29 | 2025 | General - Vascular Intervention |
| Lilly USA, LLC | $110.10 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $95.52 | 2019-2023 | Breztri, Farxiga |
| Abbvie INC. | $80.82 | 2023-2025 | Linzess, Viberzi |
| Pfizer INC. | $70.80 | 2019-2024 | |
| Abbott Laboratories | $70.68 | 2024 | Proclaim, Eterna |
| Sanofi-Aventis U.S. LLC | $60.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.25 | 2023-2024 | Tradjenta, Jardiance |
| Astellas Pharma US INC | $58.82 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $57.69 | 2022-2023 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $48.40 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $29.94 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.83 | 2022 | |
| Exact Sciences Corporation | $27.32 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $26.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.91 | 2023 | Xifaxan |
| Allergan, INC. | $14.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Straight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.